RecruitingPhase 4NCT05929755

Depo-Medrol on Psoas After LLIF

Effect of Depo-Medrol Application on the Psoas Muscle After Transpsoas LLIF on Post-operative Hip Flexor Weakness, Thigh Pain and Numbness


Sponsor

Hardeep Singh

Enrollment

80 participants

Start Date

May 12, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this study is to determine the effects of a corticosteroid administered to the psoas muscle following a transpsoas lateral lumbar interbody fusion (LLIF) on postoperative hip flexor weakness and thigh pain and numbness.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria5

  • Patients from the practices of Drs. Singh, Mallozzi, Moss
  • Transpsoas (PTP or LTP) lateral lumbar interbody fusion (LLIF) 1-3 disc levels with posterior instrumentation (Open or MIS) with or without laminectomy, must include L3-4 and/or L4-5
  • Patients who agree to be a part of the study
  • Patients with lumbar disc degeneration
  • Patients between ages of 18 and 75

Exclusion Criteria15

  • Scoliosis >10°
  • Spondylolisthesis >Grade 1
  • Flatback deformity
  • Patients with insulin dependent diabetes
  • Patients with >3 levels of fusion
  • Alternative interbodies
  • Chronic oral steroid users
  • Patients with allergy/intolerance to depo-medrol or other steroids
  • Patients requiring bilateral transpsoas approaches
  • Patients with ipsilateral symptomatic hip pathology
  • Revision fusion procedures
  • Cases involving trauma, tumor, or infection
  • Patient's not capable of providing consent themselves
  • Non-fluent English speakers (for consenting reasons)
  • Patients who are lost to follow-up before the two year follow up period

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDepo-Medrol

steroid

DRUGGel-Flow NT

hemostatic agent


Locations(1)

UConn Health

Farmington, Connecticut, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05929755


Related Trials